安理申治疗轻中度血管性痴呆的有效性及安全性分析  

The clinical study of efficiency and tolerability of Aricept in the treatment of mild,moderate vascalar dementia

作　　者：李惠敏[1] 段继豪[1] 杨丽红[1] 

机构地区：[1]河南漯河市第三人民医院内科,漯河462000

出　　处：《中国实用神经疾病杂志》2006年第4期27-28,共2页Chinese Journal of Practical Nervous Diseases

摘　　要：目的评价安理申治疗轻、中度血管性痴呆（VD）患者的有效性及安全性。方法对86例轻、中度VD患者（简易精神状态检查表（MMSE）得分10-24分]随机分为两组，治疗组和对照组，进行12周临床试验。以MMSE为主要评价指标，日常生活能力量表（ADL）和临床痴呆程度量表（CDR）为次要评价指标。结果结果表明，5mg／d安理申治疗12周时，安理申组较安慰组MMSE、ADL、CDR分数显著改善（依次P〈0．01、〈0．05、〈0．01）。自身对照研究结果显示，5mg／d安理申治疗12周时，治疗后较治疗前MMSE、CDR、ADL分数分别改善3．5、0．6、7．0分（依次P〈0．01、〈0．05、〈0．01）。安理申治疗4周时MMSE分数已有提高（P〈0．05）。结论安理申可显著改善轻中度VD病人的认知功能、痴呆程度和日常生活自理能力，且安全性和耐受性良好，是VD治疗的有效药物之一。Objective To evaluate the efficicency and safety of Aricepc for mild,moderate vein dementia（VD） Methods 86 cases of patients with mild, middle VD were randomly divided into 2 groups： the treated group and the control group. Taking 12 weeks clinical therapy. MMSE was taken as the main value target and ADL, CDR were as the secondary value target. Results After 12 weeks , the marks of MMSE, ADL, CDR of the treatment group were more improved than that of the control group（p〈0.01, 〈 0. 05. 〈0. 01）. The study indicated that the marks of MMSE, ADL, CDR compare to the comparison group 3. 5, 0. 6, 7. 0 improved （p〈0.01, 〈0.05, 〈0.01）in turn after treatment. After having been treated for 4 weeks, the marks of MMSE have been improved （p〈0. 05）. Conclusion Aricept, which can prominently improve the perceive function, the degree of dementia and the ability of taking care of oneself, is one of the efficiency ways in the treatment of VD, morever, its security and endurance is good.

关 键 词：安理申 血管性痴呆 

分 类 号：R749.13[医药卫生—神经病学与精神病学]